Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Moderate Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $41.8333.

A number of equities research analysts have commented on the company. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Thursday, March 19th. Wall Street Zen downgraded shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Guggenheim started coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective for the company. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Wedbush upped their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th.

Stoke Therapeutics Trading Up 2.5%

Shares of STOK stock opened at $32.56 on Wednesday. The business’s fifty day simple moving average is $33.09 and its 200-day simple moving average is $30.70. The company has a market cap of $1.93 billion, a PE ratio of -271.31 and a beta of 1.07. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.97) earnings per share for the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%.The business had revenue of $1.40 million during the quarter. On average, equities analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Activity

In related news, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares of the company’s stock, valued at $11,258,421.48. This represents a 10.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the sale, the chief financial officer owned 10,172 shares in the company, valued at approximately $318,790.48. The trade was a 18.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP boosted its holdings in shares of Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after acquiring an additional 423,331 shares during the last quarter. Morgan Stanley lifted its position in Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after purchasing an additional 9,108 shares during the period. Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares during the last quarter. State Street Corp boosted its holdings in Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after purchasing an additional 1,072,176 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after purchasing an additional 168,771 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.